CD274 and non-small cell lung carcinoma: In KEYNOTE-024 [NCT02142738], 305 patients (154 to pembrolizumab, 151 to platinum-based chemotherapy) who had histologically or cytologically confirmed stage IV NSCLC with PD-L1 TPS score of ≥ 50% were included in the group and then they were randomly assigned to pembrolizumab (200 mg Q3W [once every 3 weeks], up to 2 years) or platinum-based chemotherapy (4–6 cycles, Q3W, or crossover to pembrolizumab in the event of disease progression)[16] (Table 1).